By Drug Target Review2025-05-02T08:30:04
A new study by Scripps Research reveals that apremilast, an FDA-approved anti-inflammatory drug, may help reduce both alcohol consumption and pain sensitivity, offering a potential dual therapy for alcohol use disorder.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-27T13:06:00Z
2025-06-11T14:00:00
Sponsored by Eurofins Discovery
2024-01-26T13:22:42
Sponsored by bit.bio
2025-08-05T13:42:00
Sponsored by ICON plc., By Drug Target Review
2025-09-24T14:00:00
Sponsored by Eurofins Discovery
2023-05-30T13:51:56
Sponsored by BPS Bioscience
Site powered by Webvision Cloud